Overview

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is an double-blinded, randomized controlled clinical trial to determine if Venlafaxine can prevent development of depression in patients undergoing treatment for head and neck cancer.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Venlafaxine Hydrochloride